|
|||||
|
|
| 复方顺铂多相脂质体的初步研究 | |
| 引用本文： | 郭诗玫,潘秉梅. 复方顺铂多相脂质体的初步研究[J]. 沈阳药科大学学报, 1988, 0(1) |
| 作者姓名： | 郭诗玫 潘秉梅 |
| 作者单位： | 上海医科大学肿瘤医院药剂科(郭诗玫)，上海医科大学医学院化学教研室(潘秉梅) |
| 摘 要： | 本文报道了制备多相脂质体复方顺铂(102)注射液的初步研究,对注入-超声法和成膜-超声法两种制剂工艺进行了比较,抑瘤试验表明,对小鼠腹注提高剂量后,(102)和顺氯氨铂(101)对S_(180)抑瘤率都较游离顺铂高,其中(102)对S_(180)抑瘤率稍高于(101),(102)的LD_(50)0(腹注、小鼠)26.52mg/kg,而游离顺氯氨铂的LD_(50) 12.45mg/kg。 |
| 关 键 词： | 复方顺铂 脂质体 抑瘤试验 毒性试验 |
A PRIMARY INVESTIGATION OF POLYPHASE LIPOSOME CISPLATIN-CO AND ITS TOXICITY TEST |
|
| Guo Shimei,Cancer Hospital,Shanghai Medical UniversityPan Bingmei. A PRIMARY INVESTIGATION OF POLYPHASE LIPOSOME CISPLATIN-CO AND ITS TOXICITY TEST[J]. Journal of Shenyang Pharmaceutical University, 1988, 0(1) | |
| Authors: | Guo Shimei Cancer Hospital Shanghai Medical UniversityPan Bingmei |
| Affiliation: | Guo Shimei,Cancer Hospital,Shanghai Medical UniversityPan Bingmei,Department of Organic Chemistry,Shanghai Medical University |
| Abstract: | In this paper, a study on the preparation of the suspension of polyphaseliposome cisplatin-co(102) is reported. Cisplatin-co (102) is composed of cisplatin, oleic acid, soybean lecithin,leucitin cholesterol, exeipients(Tween-80 and PVP etc.), 101 being without oleicacid, but similar to remainders of 102. A comparsion was made between theinjection-ultrasonic method and the method of membrane-forming-ultrasonic, whichwere used as in preparing 102 and 101. Preliminary results showed that 102 was stronger inhibitor against sarcomaS_(180) than 101, when intraperitoneally injected in mice. The new dosage form forantitumor agent 102 might be used clinically due to its higher antitumor activity,and lower toxicity. But further studies on it will be needed. |
| Keywords: | Cisplatin-co Polyphase liposome Tumor inhibitor test Toxicity test |
| 本文献已被 CNKI 等数据库收录！ | |